What is the procedure for an anti-sensitivity test for iron sucrose (iron) injection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Iron Sucrose Does Not Require a Test Dose

Iron sucrose does not require a test dose before administration, unlike iron dextran. This is a critical distinction that simplifies administration and reduces unnecessary delays in treatment 1, 2.

Key Administration Protocol for Iron Sucrose

No Test Dose Required

  • Iron sucrose carries no "black-box" warning and a test dose is not required before administration 2
  • The FDA label for iron sucrose (Venofer) does not mandate test dosing 1
  • This contrasts sharply with iron dextran, which requires a mandatory 25 mg test dose administered as a slow IV bolus with a 1-hour observation period 3, 4

Standard Dosing Regimens

For routine administration:

  • 200 mg IV over 60 minutes (infusion) OR 200 mg over 2-5 minutes (slow IV bolus) 4
  • Repeated administration every 2-3 weeks until total required dose is achieved 4
  • Maximum individual dose should not exceed 300 mg 4
  • Maximum total dose should be 1000 mg 4

Alternative rapid administration:

  • 100 mg can be administered over several minutes as an undiluted IV push 2, 5
  • 200 mg as a 2-minute bolus injection has been shown safe in prospective studies of 2,297 injections 6

Safety Monitoring Requirements

During Administration

  • Monitor patients for signs and symptoms of hypersensitivity during and for at least 30 minutes after completion of the infusion 1
  • Most reactions occur within 30 minutes of completion 1
  • Personnel and therapies must be immediately available for treatment of serious hypersensitivity reactions 1

Vital Sign Monitoring

  • Monitor for clinically significant hypotension following each administration 1
  • Blood pressure changes should be recorded and compared to baseline 5

Important Clinical Considerations

When Test Dosing IS Recommended

While not required for iron sucrose, test doses are strongly recommended at physician discretion if patients have exhibited sensitivities to iron dextran or other IV iron preparations, or who have multiple drug allergies 3. In such cases:

  • Administer 25 mg as a slow IV push 3
  • Observe for reaction before proceeding with full dose

Safety in Previously Sensitive Patients

  • Iron sucrose can be safely administered to patients with documented hypersensitivity to iron dextran 7, 8
  • In a study of 23 hemodialysis patients with documented iron dextran sensitivity, no serious adverse reactions occurred after 223 doses of iron sucrose 8
  • Iron sucrose may even be safely administered to patients with previous hypersensitivity to ferric gluconate 7

Contraindications

  • Do not administer to patients with active infection 4
  • Do not administer to patients with evidence of iron overload 1

Common Adverse Events

The most frequent adverse event is mild, transient metallic taste occurring in approximately 18% of injections, which causes no significant distress 6. Other potential reactions include:

  • Hypotension, hypertension 4
  • Nausea, vomiting, diarrhea 4
  • Pain at injection site 6
  • Fever, dyspnea, pruritus, headache, dizziness 4

Serious hypersensitivity reactions are extremely rare with iron sucrose compared to iron dextran 2, 5.

Laboratory Monitoring

  • Do not perform serum iron measurements for at least 48 hours after IV dosing, as transferrin saturation values increase rapidly 1
  • Transferrin and ferritin levels can be measured reliably 48 hours after administration 2
  • Monitor hemoglobin, hematocrit, serum ferritin, and transferrin saturation periodically 1

References

Research

Iron sucrose: the oldest iron therapy becomes new.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Parenteral Iron Administration Regimen

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001

Research

Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005

Research

Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.